Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Yang

Showing results (141-150 of 148) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 148 results.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
Research Square|May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesisKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Biochemical Pharmacology|December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitroKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young AdultsAdam S DuVall, Jennifer McNeer, Matthew C Cheung, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
ACS Nano|March 2, 2026
Technology Roadmap of Bioinspired Computing HardwareShuang Wang, Zhiyuan Li, Mengjiao Pei, et al.
Pageof 15

Showing results (141-150 of 148) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 148 results.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
Research Square|May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesisKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
Biochemical Pharmacology|December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitroKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
The Lancet. Haematology|November 12, 2022
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M Watts, Maria R Baer, Jay Yang, et al.
Blood Advances|February 11, 2026
ASH 2026 Guidelines for Frontline Management of Acute Lymphoblastic Leukemia in Adolescents and Young AdultsAdam S DuVall, Jennifer McNeer, Matthew C Cheung, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
ACS Nano|March 2, 2026
Technology Roadmap of Bioinspired Computing HardwareShuang Wang, Zhiyuan Li, Mengjiao Pei, et al.
Pageof 15